These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 31434953)

  • 21. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
    Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach.
    Schott CR; Koehne AL; Sayles LC; Young EP; Luck C; Yu K; Lee AG; Breese MR; Leung SG; Xu H; Shah AT; Liu HY; Spillinger A; Behroozfard IH; Marini KD; Dinh PT; Pons Ventura MV; Vanderboon EN; Hazard FK; Cho SJ; Avedian RS; Mohler DG; Zimel M; Wustrack R; Curtis C; Sirota M; Sweet-Cordero EA
    Clin Cancer Res; 2024 Feb; 30(4):849-864. PubMed ID: 37703185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution.
    Castillo-Ecija H; Monterrubio C; Pascual-Pasto G; Gomez-Gonzalez S; Garcia-Dominguez DJ; Hontecillas-Prieto L; Resa-Pares C; Burgueño V; Paco S; Olaciregui NG; Vila-Ubach M; Restrepo-Perdomo C; Cuadrado-Vilanova M; Balaguer-Lluna L; Perez-Jaume S; Castañeda A; Santa-Maria V; Roldan M; Suñol M; de Alava E; Mora J; Lavarino C; Carcaboso AM
    J Control Release; 2020 Aug; 324():440-449. PubMed ID: 32497782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance.
    Avnet S; Lemma S; Cortini M; Pellegrini P; Perut F; Zini N; Kusuzaki K; Chano T; Grisendi G; Dominici M; De Milito A; Baldini N
    Oncotarget; 2016 Sep; 7(39):63408-63423. PubMed ID: 27566564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A humanized bone microenvironment uncovers HIF2 alpha as a latent marker for osteosarcoma.
    Wagner F; Holzapfel BM; Martine LC; McGovern J; Lahr CA; Boxberg M; Prodinger PM; Grässel S; Loessner D; Hutmacher DW
    Acta Biomater; 2019 Apr; 89():372-381. PubMed ID: 30836200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507.
    Fleuren ED; Versleijen-Jonkers YM; van de Luijtgaarden AC; Molkenboer-Kuenen JD; Heskamp S; Roeffen MH; van Laarhoven HW; Houghton PJ; Oyen WJ; Boerman OC; van der Graaf WT
    Clin Cancer Res; 2011 Dec; 17(24):7693-703. PubMed ID: 22038993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma.
    Pahl JH; Ruslan SE; Buddingh EP; Santos SJ; Szuhai K; Serra M; Gelderblom H; Hogendoorn PC; Egeler RM; Schilham MW; Lankester AC
    Clin Cancer Res; 2012 Jan; 18(2):432-41. PubMed ID: 22090361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium.
    Harrison DJ; Gill JD; Roth ME; Zhang W; Teicher B; Erickson S; Gatto G; Kurmasheva RT; Houghton PJ; Smith MA; Kolb EA; Gorlick R
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28222. PubMed ID: 32207565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A tissue microarray study of osteosarcoma: histopathologic and immunohistochemical validation of xenotransplanted tumors as preclinical models.
    Mayordomo E; Machado I; Giner F; Kresse SH; Myklebost O; Carda C; Navarro S; Llombart-Bosch A
    Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):453-61. PubMed ID: 20436344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
    Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
    Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model.
    Higuchi T; Miyake K; Oshiro H; Sugisawa N; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Biochem Biophys Res Commun; 2019 May; 513(2):326-331. PubMed ID: 30955860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells.
    Di Conza G; Buttarelli M; Monti O; Pellegrino M; Mancini F; Pontecorvi A; Scotlandi K; Moretti F
    Mol Cancer Ther; 2012 Jun; 11(6):1247-56. PubMed ID: 22461661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma.
    Hingorani P; Zhang W; Piperdi S; Pressman L; Lin J; Gorlick R; Kolb EA
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):733-40. PubMed ID: 19224214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ethyl-2-amino-pyrrole-3-carboxylates are novel potent anticancer agents that affect tubulin polymerization, induce G2/M cell-cycle arrest, and effectively inhibit soft tissue cancer cell growth in vitro.
    Boichuk S; Galembikova A; Zykova S; Ramazanov B; Khusnutdinov R; Dunaev P; Khaibullina S; Lombardi V
    Anticancer Drugs; 2016 Aug; 27(7):620-34. PubMed ID: 27129079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Tumor Vascular CD99 Inhibits Tumor Growth.
    Huijbers EJM; van der Werf IM; Faber LD; Sialino LD; van der Laan P; Holland HA; Cimpean AM; Thijssen VLJL; van Beijnum JR; Griffioen AW
    Front Immunol; 2019; 10():651. PubMed ID: 31001265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma.
    Pascual-Pasto G; Resa-Pares C; Castillo-Ecija H; Aschero R; Baulenas-Farres M; Vila-Ubach M; Burgueño V; Balaguer-Lluna L; Cuadrado-Vilanova M; Olaciregui NG; Martinez-Velasco N; Perez-Jaume S; de Alava E; Tirado OM; Lavarino C; Mora J; Carcaboso AM
    Biochem Pharmacol; 2023 Feb; 208():115408. PubMed ID: 36603685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
    Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
    Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of ABC Transporters in Osteosarcoma and Ewing's Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?
    Serra M; Hattinger CM; Pasello M; Casotti C; Fantoni L; Riganti C; Manara MC
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Preliminary report of combination chemotherapy including Arsenic trioxide for stage III osteosarcoma and Ewing sarcoma].
    Guo W; Tang XD; Tang S; Yang Y
    Zhonghua Wai Ke Za Zhi; 2006 Jun; 44(12):805-8. PubMed ID: 16889724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.